Melanoma Metastasis Diagnosis is Possible through Clinical Blood Tests in Near Future
Researchers from Yale University have identified seven bio-markers which can help in the diagnosis of the metastasis of the harmful melanoma cancer. The results of the study are published in the April 2011 issue of the journal Clinical Cancer Research.
The study involved 216 melanoma patients. 50 percent of them were in stage 1 and in stage 2. The other half of patients were in metastatic stage. The study identified the biomarkers MIA, CEACAM, GDF-15, ICAM-1, osteopontin, TIMP-1 and S100B in the blood of these patients.
83 percent patients from the metastatic group had raised levels of at least one of these indicator molecules. 76 percent patients from stage 1 and stage 2 had no rise of these biomarkers in their blood.
Though further study is warranted, this present research has raised the hope that metastasis can be diagnosed through clinical tests in near future.
As of now, the process of diagnosis is costly and not effective. However, the risk of metastasis of melanoma is 10 percent in stage 1A and 70 percent in stage 3C.